COMMUNIQUÉS West-GlobeNewswire

NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
25/03/2026
The collaboration aims to uncover clinically actionable patient subpopulations and biomarker-driven treatment insights from a landmark precision-oncology trial TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark [...]
CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory
25/03/2026
DIJON, France – 25 March 2026 (07:20 AM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free [...]
Annual General Meeting 2026: Tecan proposes the election of three new members of the Board of Directors and a new Chairman
25/03/2026
Annual General Meeting 2026: Tecan proposes the election of three new members of the Board of Directors and a new Chairman Nina Beikert, Gitte Pugholm Aabo and Guillaume Daniellot will be proposed as new members of the [...]
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
25/03/2026
Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&D investments [...]
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
25/03/2026
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a phase 2 trial in Chinese people with type 2 diabetes, UBT251 [...]
Zelluna ASA [ZLNA]: Annual Report 2025
25/03/2026
Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces that the Board of [...]
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
25/03/2026
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class [...]
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
24/03/2026
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “ [...]
Solana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026
24/03/2026
NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to [...]
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
24/03/2026
Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in late Q4 2026 Reports [...]
MitoSynergy Introduces BioCopper1® - A Clinically Proven Nutraceutical Designed for Mitochondrial Performance
25/03/2026
Scottsdale, AZ, March 24, 2026 (GLOBE NEWSWIRE) -- MitoSynergy , a science-driven wellness company focused on cellular and mitochondrial health, today announced the introduction of an improved BioCopper1®, a patented [...]
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
24/03/2026
Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (Euronext: DBV – ISIN [...]
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
24/03/2026
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
24/03/2026
Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total [...]
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
24/03/2026
POMPANO BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal [...]
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
24/03/2026
CALGARY, Alberta, March 24, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
DBV Technologies intégrera les indices CAC Mid 60 et SBF 120 à l'issue de la révision annuelle d'Euronext Paris
24/03/2026
Châtillon, France, le 24 mars (22 :30 CET) 2026 DBV Technologies intégrera les indices CAC Mid 60 et SBF 120 à l'issue de la révision annuelle d'Euronext Paris Les modifications sont entrées en vigueur le lundi 23 mars [...]
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
24/03/2026
Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026 Completed 52-week follow-up from Phase II trial [...]
Spectral AI Announces 2025 Fourth Quarter and Full Year Financial Results and Introduces Revenue Guidance for 2026
24/03/2026
Overview Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 Million Cash Rose to $15.4 Million at December 31, 2025 DALLAS, March 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. ( [...]

Pages